Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 14/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1234096 | 0.78 | PIK3CG (0.56) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL1234689 | 0.77 | PIK3CG (0.54) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL1234119 | 0.77 | PIK3CG (0.57) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL12826950 | 0.76 | PIK3CG (0.53) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL1234639 | 0.76 | PIK3CG (0.53) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL1234641 | 0.75 | PIK3CG (0.64) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL1235217 | 0.75 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL1234107 | 0.74 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL1233963 | 0.74 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL1233961 | 0.74 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888379-B2 | N-[5-(5-formyl-2-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide; autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer | MERCK SERONO SA (CH) | 2011-02-15 | — | — | US | claimed |
| US-20080200463-A1 | Thiazole Derivatives and Use Thereof | LABORATOIRES SERONO SA (CH) | 2008-08-21 | — | — | US | claimed |
| US-20110071113-A1 | Thiazole Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2011-03-24 | — | — | US | disclosed |
| US-20110071113-A1 | Thiazole Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2011-03-24 | — | — | US | disclosed |
| US-7888379-B2 | N-[5-(5-formyl-2-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide; autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer | MERCK SERONO SA (CH) | 2011-02-15 | — | — | US | disclosed |
| US-7888379-B2 | N-[5-(5-formyl-2-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide; autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer | MERCK SERONO SA (CH) | 2011-02-15 | — | — | US | disclosed |
| US-7888379-B2 | N-[5-(5-formyl-2-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide; autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer | MERCK SERONO SA (CH) | 2011-02-15 | — | — | US | disclosed |
| US-20080200463-A1 | Thiazole Derivatives and Use Thereof | LABORATOIRES SERONO SA (CH) | 2008-08-21 | — | — | US | disclosed |
| US-20080200463-A1 | Thiazole Derivatives and Use Thereof | LABORATOIRES SERONO SA (CH) | 2008-08-21 | — | — | US | disclosed |
| US-20080200463-A1 | Thiazole Derivatives and Use Thereof | LABORATOIRES SERONO SA (CH) | 2008-08-21 | — | — | US | disclosed |
| EP-1888573-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006125807-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200463-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | PIK3CG 2526/4885PIK3CD 1844/4885PIK3CA 1647/4885 |
| US-20110071113-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | PIK3CG 2526/4885PIK3CD 1844/4885PIK3CA 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.